PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumorsMónica Tang, Michael Friedländer, James Scurry et al.|Gynecologic Oncology|2019Cited by 88
Coping strategies, trajectories, and their associations with patient-reported outcomes among women with ovarian cancerPenelope M. Webb, Vanessa L. Beesley, David Smith et al.|Supportive Care in Cancer|2018Cited by 45
A healthy lifestyle and survival among women with ovarian cancerJessy Hansen, Christina M. Nagle, Torukiri I Ibiebele et al.|International Journal of Cancer|2020Cited by 43
Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns)Vanessa L. Beesley, Michael Friedländer, Tanya L. Ross et al.|Gynecologic Oncology|2021Cited by 36
Insomnia and its association with quality of life in women with ovarian cancerTanya L. Ross, Vanessa L. Beesley, Anna DeFazio et al.|Gynecologic Oncology|2020Cited by 33